Diagnostics in China
This article was originally published in The Gray Sheet
Executive Summary
China Medical Technologies broadens its in vitro diagnostic market presence in China through the purchase of Beijing Bio-Ekon Biotechnology for $28.8 million, announced Nov. 26. The acquired firm offers enzyme-linked immunosorbent assays and semi-automatic, enhanced chemiluminescence immunoassay (ECLIA) analyzers and related reagents in China, and expects to seek approval in China next year for a fully automatic version. CMT, which also offers ECLIA products, acquired fluorescent in situ hybridization diagnostics technology in February (1"The Gray Sheet" Feb. 12, 2007, p. 8)
You may also be interested in...
CMT Targets Cancer, Prenatal Testing Markets In China
China Medical Technologies plans to exploit China's efforts to expand health care access by launching prenatal and postnatal tests as well as cancer diagnostics based on newly acquired fluorescent in situ hybridization technology
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.